This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Facioscapulohumeral muscular dystrophy (FSH muscular dystrophy)Facioscapulohumeral Muscular Dystrophy (FSHD)

ICD-10G71.0
Special Copayment ReductionV012 · 5 years
A. SynonymsFacioscapulohumeral muscular dystrophy, Landouzy-Dejerine muscular dystrophy, FSH muscular dystrophy
B. Adult onsetModerate to high — typically onset in the 20s~30s; some with early childhood onset (large D4Z4 deletions), some not manifesting until their 50s
1. History1884 Landouzy and Dejerine described a familial myopathy characterized by facial and shoulder weakness; 1992 association with D4Z4 deletion at 4q35 on chromosome 4 confirmed; 2010 mechanism of ectopic DUX4 expression established
2. CausesFSHD1: contraction of the 4q35 D4Z4 macrosatellite repeat (<11 repeat units, normal 11~100) + permissive 4qA haplotype; FSHD2: mutations in epigenetic regulator genes such as SMCHD1 + D4Z4 hypomethylation
3. GeneticsFSHD1 autosomal dominant (standard form 95%); FSHD2 digenic; D4Z4 repeat number ≤3 units associated with early onset and severe phenotype; penetrance 95% or more; phenotype varies even with the same repeat number
4. Epidemiology1/8,000~1/20,000; third most common hereditary muscle disease; about 870,000 people estimated worldwide; no accurate statistics in Korea, but on the scale of hundreds to thousands
5. PathophysiologyD4Z4 repeat contraction/hypomethylation → permits DUX4 transcription → ectopic expression of DUX4 protein → activation of muscle cell death programs, oxidative stress, immune activation
6. SymptomsFacial muscle weakness (inability to fully close the eyes, horizontal smile), winged scapula, upper arm weakness; lower limb involvement (tibialis anterior, hip extensors); retinal vasculopathy and hearing loss in some
7. SignsWinged scapula (protrusion of the medial border of the scapula on arm elevation), Beevor sign (upward movement of the umbilicus), facial weakness (inability to fully close the eyelids); serum CK mildly to moderately elevated
8. ScreeningD4Z4 repeat number analysis for facial and scapular weakness in people in their 20s~30s with a family history; new screening: quantitative D4Z4 methylation analysis
9. DiagnosisD4Z4 repeat number measurement (Southern blot, optical genome mapping) + confirmation of the 4qA haplotype → FSHD1 diagnosis; SMCHD1 gene analysis + D4Z4 hypomethylation → FSHD2; muscle biopsy not required (nonspecific findings)
10. TreatmentNo approved disease-modifying treatment; active clinical trials of DUX4-suppressing ASOs and siRNAs; clinical trial of losrinostat (HDAC inhibitor); supportive treatment (surgery for winged scapula, orthoses, physical therapy)
11. PrognosisSlow progression with large individual variation; about 20% lose ambulation; cardiopulmonary involvement rare; retinal vasculopathy and hearing loss affect quality of life; overall life expectancy close to normal
12. PreventionGenetic counseling; PGT-M possible for FSHD1; avoidance of sunlight exposure (prevention of retinal vasculopathy); early detection of complications by regular monitoring
References10 key PMIDs/DOIs

1. History

Facioscapulohumeral muscular dystrophy (FSHD) entered the medical literature in 1884, when the French neurologists Louis Landouzy and Joseph Dejerine first described it as a familial myopathy with characteristic weakness of the facial muscles and the shoulder and upper arm muscles. They distinguished this disease from other myopathies by its unique distribution pattern: it appears gradually in adulthood, facial muscle involvement reduces facial expression, and the shoulder girdle and upper arm muscles are selectively weakened. The name Landouzy-Dejerine muscular dystrophy was used for a long time.

In 1992, an international collaborative research team including Santamaria (Wijmenga, Padberg) et al. discovered that deletion (contraction) of a macrosatellite repeat unit called D4Z4 in the 4q35 subtelomeric region on the long arm of chromosome 4 is associated with FSHD. It was subsequently shown that the presence of the permissive 4qA haplotype is a necessary condition (Lemmers 2002). An important finding was that a similar D4Z4 repeat exists on chromosome 10 as well as chromosome 4, but deletions on chromosome 10 do not cause FSHD because chromosome 10 lacks the 4qA haplotype.

In 2010, research published in Nature Genetics by Lantos (Lemmers, de Knijff) et al. demonstrated that ectopic expression of the DUX4 (double homeobox 4) gene located within the D4Z4 repeat is the core pathogenic mechanism of FSHD, settling a debate over the pathogenesis of FSHD spanning some 30 years. In 2012, it was shown that FSHD2 arises from D4Z4 hypomethylation due to SMCHD1 gene mutations even without a D4Z4 deletion. Currently, the development of therapies targeting DUX4 is actively underway worldwide.

2. Causes

FSHD is divided into two genetic mechanisms.

FSHD1 (about 95% of all patients): The cause is contraction of the number of D4Z4 macrosatellite repeat units in the 4q35.2 subtelomeric region of chromosome 4 from normal (11~100 repeats) to 10 repeats or fewer (1~10, pathologically 1~10). When repeat units decrease to 10 or fewer, the chromatin of the D4Z4 region relaxes (open structure), permitting transcription of the DUX4 gene, which should normally be repressed. However, for DUX4 to produce stable mRNA and be translated into a toxic protein, the permissive 4qA haplotype containing the adjacent pLAM polyadenylation signal must be present. With the 4qB haplotype instead of 4qA, FSHD does not develop even with a D4Z4 deletion.

FSHD2 (about 5%): The D4Z4 repeat number is normal (11~100), but due to loss-of-function mutations in the SMCHD1 (Structural Maintenance of Chromosomes flexible Hinge Domain containing 1) gene, the D4Z4 repeat is abnormally hypomethylated, resulting in ectopic expression of DUX4. FSHD2 manifests with the combination (digenic) of an SMCHD1 mutation and the 4qA haplotype, and neither SMCHD1 alone nor 4qA alone causes disease. Rarely, abnormalities in epigenetic regulator genes such as DNMT3B and LRIF1 are also identified in FSHD2.

Repeat number and severity: the fewer the D4Z4 repeats (1~3 units), the earlier the onset and the more severe the phenotype; intermediate severity is observed with 4~7 units, and mild or incompletely penetrant phenotypes with 8~10 units.

3. Genetics

FSHD1 follows an autosomal dominant mode of inheritance, and 50% of the children of an affected parent inherit the D4Z4-deleted allele. Penetrance increases with age, and more than 95% of mutation carriers show clinical symptoms at some point. However, asymptomatic carriers sometimes exist even within families with the same D4Z4 repeat number (incomplete penetrance), which must be considered in genetic counseling.

New mutations (de novo): about 10~30% of FSHD1 arises from new deletions not found in the parents. Gonadal mosaicism is also not uncommon, so it must be explained that the recurrence risk for siblings is not zero even when the family history is negative. FSHD2 follows a digenic pattern combining autosomal dominant inheritance of the SMCHD1 mutation with dominant inheritance of the 4qA haplotype, and the SMCHD1 mutation alone does not cause FSHD.

Diagnostic molecular genetics: the diagnosis of FSHD1 is established by meeting two conditions: (1) D4Z4 repeat number analysis (confirming ≤10 repeat units) + (2) confirmation of the permissive 4qA haplotype. Traditionally, Southern blot was the standard method, but recently optical genome mapping (OGM) has emerged as an alternative method with high accuracy. Quantitative D4Z4 methylation analysis is being increasingly introduced as a highly sensitive method for screening both FSHD1 and FSHD2. The latest 2024 diagnostic guidelines recommend the integrated use of methylation analysis and repeat number analysis.

4. General epidemiology

FSHD is the third most common hereditary muscle disease worldwide, with a prevalence varying by report from 1/8,000 to 1/20,000. About 870,000 people are estimated to be affected worldwide, and the actual prevalence may be higher due to underdiagnosis of mild patients. FSHD is distributed worldwide regardless of race, sex, or geographic location, and founder effects in specific populations are not large.

Sex differences: FSHD affects men and women equally, but some studies have reported that men show an earlier age of onset and a more severe clinical course. Women tend to have a somewhat higher proportion of milder symptoms or incomplete penetrance even with the same D4Z4 repeat number, and the possibility that sex hormones influence clinical expression is being studied.

Domestic status: data on the exact prevalence of FSHD in Korea are limited, but it is estimated on the scale of hundreds to thousands in rare disease registration records. It is managed under Special Copayment Reduction G71.0 and is the muscular dystrophy subtype diagnosed most often after DMD in neuromuscular specialty clinics. The early childhood-onset form occurs in those with large D4Z4 deletions (1~3 repeat units), accounts for about 5% of all FSHD, and is often accompanied by hearing impairment and retinal vasculopathy.

5. Pathophysiology

The pathogenesis of FSHD is now widely accepted as muscle cell toxicity due to ectopic expression of the DUX4 (double homeobox 4) transcription factor.

Repression of DUX4 in the normal state: The D4Z4 repeat array normally maintains dense methylation (hypermethylation) and a repressive chromatin structure (heterochromatin). In this environment, DUX4 is not transcribed in muscle cells and is expressed only in embryonic cells and germ cells. Several epigenetic regulators, including SMCHD1, DNMT3B, and PRC2 (Polycomb Repressive Complex 2), are involved in this repression mechanism.

Derepression of DUX4 in FSHD: When methylation of the D4Z4 region decreases and chromatin relaxes due to reduced D4Z4 repeat number (FSHD1) or loss of SMCHD1 function (FSHD2), transcription of DUX4 is permitted. The presence of the pLAM polyadenylation signal of the 4qA haplotype stabilizes DUX4 mRNA and allows translation. The DUX4 protein is a transcription factor that activates a totipotency gene network during embryonic development, and when ectopically expressed in muscle cells it triggers several mechanisms that are lethal to muscle cells.

DUX4-mediated muscle cell toxicity: (1) Induction of cell death (apoptosis and caspase-dependent death). (2) Activation of the p53 pathway. (3) Oxidative stress (increased reactive oxygen species). (4) RNA toxicity (expression of harmful genes by the double homeobox transcription factor). (5) Activation of innate immunity (infiltration of inflammatory cells into muscle). (6) Reduced satellite cell regenerative capacity through suppression of PAX7 expression. These mechanisms act in combination to cause irreversible loss of muscle fibers. DUX4 is expressed at very low levels (less than 1/1,000 of all myonuclei), but its cytotoxicity is potent.

6. Symptoms

FSHD is characterized by selective weakness of the facial muscles, scapular stabilizer muscles, and upper arm muscles, and symptoms show a stepwise descending progression from top to bottom. Symptom onset is typically in the teens~30s, with very large individual variation.

Facial muscle involvement: Facial weakness is the most characteristic early finding of FSHD. Inability to fully close the eyelids (lagophthalmos) causes the eyes to remain half open during sleep or causes dry eye. Inability to purse the lips or blow air through the lips (whistling, balloons), a horizontal smile (a flat smile in which the corners of the mouth do not rise on either side), and reduced facial expression appear. Facial asymmetry is also often present.

Shoulder girdle and upper arm involvement: Weakness of the serratus anterior, rhomboids, and lower trapezius, which stabilize the scapula, causes winging scapula. When the arms are raised forward, the scapulae protrude backward like wings. Weakness of the biceps and triceps may produce a muscle-loss pattern in which the upper arm becomes thin, the opposite of the characteristic "drink bottle" shape (Popeye arm). Difficulty raising the arms above the shoulders limits daily activities such as combing hair and reaching objects on shelves.

Lower limb involvement: Weakness of the abdominal muscles (lower rectus abdominis) produces Beevor's sign (the umbilicus moves upward during a sit-up). In the lower limbs, the tibialis anterior (ankle dorsiflexor) and then the hip extensors (gluteals) weaken. Foot drop and increased lumbar lordosis may appear. About 20% of all patients lose the ability to walk.

Extramuscular involvement: Retinal vasculopathy (Coats disease-like): retinal microvascular abnormalities may cause exudation, hemorrhage, and detachment, and are common especially in the childhood-onset form with few D4Z4 repeats. Hearing loss (high-frequency sensorineural): frequency of 10~50% in patients with large deletions. Scoliosis and respiratory muscle involvement are not uncommon in the childhood-onset and severe forms.

7. Signs

Key signs of FSHD on physical examination: Scapular winging: when the patient is observed from behind while extending the arms forward or pushing against a wall with the hands, protrusion of the medial border of the scapula is observed. This results from weakness of the serratus anterior and lower trapezius and is a key sign that raises suspicion of FSHD. Facial weakness: reduced eyelid closure strength (inability to keep the eyes closed against resistance), inability to protrude the lips, inability to puff out the cheeks. Beevor's sign: the umbilicus moves cranially (upward) when the patient flexes the head or performs a sit-up. It occurs when the upper rectus abdominis is relatively preserved compared with weakness of the lower rectus abdominis, and it is a relatively specific sign in FSHD.

Serum CK: mild to moderate elevation is common (2~5 times normal). Marked elevation is rare, and CK may be normal. Electromyography: myopathic changes are observed but are nonspecific. Nerve conduction is normal. Muscle MRI: selective fatty replacement of the facial and periscapular muscles is identified on T1-weighted images. In the lower limbs, early involvement of the tibialis anterior and adductors is characteristic. Inflammatory changes (muscle edema) on STIR images suggest active lesions.

Ophthalmologic examination: in FSHD patients, especially the childhood-onset form, ophthalmologic examination including fluorescein angiography is performed to detect retinal vasculopathy early. Hearing tests (pure-tone audiometry, ABR) are also recommended for the childhood-onset form and for patients with few repeats.

8. Screening

The key to screening for FSHD is recognition of the characteristic clinical phenotype (facial weakness + winged scapula) and confirmation of family history. When the clinical findings are typical, one can proceed directly to genetic testing even without serum CK and electromyography.

Primary screening clues: (1) a combination of slowly progressive facial weakness (reduced expression, difficulty fully closing the eyes) + periscapular weakness in the 20s~40s. (2) Family members with similar symptoms (autosomal dominant). (3) Winged scapula found incidentally in a young adult. (4) A combination of unexplained high-frequency sensorineural hearing loss + muscle weakness (childhood-onset form).

Genetic screening: to diagnose FSHD1, the D4Z4 repeat number is measured in peripheral blood DNA and the permissive 4qA haplotype is confirmed. Traditionally Southern blot is the standard, but optical genome mapping (OGM) and D4Z4 methylation analysis are being introduced as new screening tools. D4Z4 methylation analysis is a highly sensitive method that distinguishes FSHD1 and FSHD2 simultaneously, and the 2024 guidelines of the European society of clinical genetics recommend active use of methylation analysis in FSHD diagnosis.

Family screening: genetic testing is offered to the parents, siblings, and children of patients with confirmed FSHD1. Even if asymptomatic, regular clinical monitoring (ophthalmologic and hearing tests, muscle function assessment) is started when a D4Z4 deletion is identified.

9. Diagnosis

FSHD is confirmed by molecular genetic testing, and integration with clinical findings is essential.

FSHD1 diagnosis: Step 1 — D4Z4 repeat number measurement: the size of the chromosome 4 D4Z4 fragment is measured by EcoRI/BlnI double-digest Southern blot. 10 or fewer (generally corresponding to ≤35~38 kb) is the positive criterion. Distinguishing the D4Z4 of chromosomes 4 and 10 is important. Optical genome mapping (OGM) has recently become a highly accurate alternative to Southern blot. Step 2 — confirmation of the 4qA haplotype: the FSHD1 diagnosis is established only if 4qA molecular markers (pLAM, etc.) are positive. FSHD2 diagnosis: identification of an SMCHD1 gene mutation (whole exome analysis or full gene analysis) + quantitative D4Z4 methylation analysis (confirming hypomethylation) + positive 4qA haplotype.

Muscle biopsy: in FSHD, muscle biopsy is not essential for establishing the diagnosis. Biopsy findings show nonspecific myopathic changes such as fiber size variation, internalized nuclei, and some inflammatory cell infiltration. It is performed adjunctively only when genetic testing is negative but clinical suspicion is strong. Functional assessment: multisystem functional assessment including the 6-minute walk test (6MWT), upper limb reachable workspace, hand strength measurement, pulmonary function tests, ophthalmologic examination (retinal fluorescein angiography), and hearing tests is performed regularly from the time of diagnosis.

10. Treatment

There is currently no FDA- or EMA-approved disease-modifying treatment for FSHD. However, development of therapies targeting DUX4 is actively underway, with several phase 1/2 clinical trials in progress.

DUX4-suppressing treatment (under study): Antisense oligonucleotides (ASOs): ASOs targeting the polyadenylation signal or splicing of DUX4 mRNA have been shown to effectively suppress DUX4 expression in cell and animal models and are progressing to clinical trials. siRNA- and microRNA-based therapies are also in development. Small-molecule DUX4 inhibitors: the p38 MAPK inhibitor class (losmapimod) suggested the possibility of suppressing DUX4 expression and improving muscle function, and phase 2/3 clinical trials were conducted. Initial results were mixed, but further research is underway.

HDAC inhibitors: Losrinostat (HDAC inhibitor) is in clinical trials as a strategy to suppress DUX4 expression by restoring D4Z4 methylation. Short-chain fatty acids such as sodium butyrate have also shown reported preclinical effects.

Surgical treatment — scapulothoracic fusion: In patients with severe functional limitation due to winged scapula, surgery to fix the scapula to the chest wall is performed to improve arm elevation. When appropriate surgical indications are selected through systematic evaluation, it is effective in improving quality of life. Risks include pneumothorax, nerve injury, and surgery-related complications.

Supportive treatment: Physical therapy (compensatory exercises for winged scapula, lower limb strength training), orthoses (AFO, prevention of foot drop), fall prevention. Ophthalmologic monitoring and laser photocoagulation (treatment of retinal vasculopathy). Hearing aids (sensorineural hearing loss). Scoliosis correction surgery (in severe cases). Respiratory support (severe pediatric form). Pain management (periscapular muscle pain, low back pain).

11. Prognosis

FSHD is a disease with slow progression and very large individual variation. About 20% of all patients lose the ability to walk (wheelchair dependence), while the remaining 80% maintain independent ambulation throughout life. The childhood-onset form with large D4Z4 deletions (1~3 units) shows the most severe course and may be accompanied by wheelchair dependence in the teens, hearing impairment, and retinal vasculopathy.

The adult-onset form progresses slowly over decades, and reduced shoulder function is the most important cause of disability. Facial weakness affects social interaction, and the psychosocial burden from reduced expression and inability to smile is great. Lumbar lordosis and scoliosis cause pain.

Cardiopulmonary involvement is rare in typical adult-onset FSHD. Life expectancy is known not to differ greatly from that of the general population. However, vision loss due to retinal vasculopathy, hearing loss, chronic pain, and depression can markedly reduce quality of life, so a multidisciplinary approach and regular monitoring are important. Pain control, psychological support, and promotion of social participation should be included among the goals of comprehensive management.

12. Prevention

Fundamental prevention of FSHD is achieved through genetic counseling and prenatal and preimplantation genetic diagnosis. FSHD1 is autosomal dominant, and 50% of the children of an affected parent inherit the D4Z4-deleted allele. Through preimplantation genetic diagnosis (PGT-M), embryos with a D4Z4 deletion can be identified and their implantation avoided, which is the most proactive method for preventing recurrence especially of the childhood-onset form with 1~3 repeat units. Prenatal diagnosis (CVS or amniocentesis) is also possible, and the parents decide whether to continue the pregnancy based on the results.

Prevention of retinal vasculopathy: a hypothesis has been raised that excessive solar UV exposure may worsen retinal vascular lesions, so wearing UV-blocking glasses and avoiding sunlight exposure are recommended. In patients with 1~7 D4Z4 repeat units, retinal fluorescein angiography by an ophthalmologist is performed regularly (every 1~2 years) from the early stage of diagnosis. When active retinal exudation or neovascularization develops, laser photocoagulation or anti-VEGF treatment is given.

Hearing protection: exposure to noisy environments is minimized, and in patients with the childhood-onset form, early hearing tests and hearing aid prescription protect language development and educational opportunities. Fall prevention: to reduce the risk of falls due to foot drop and lower limb weakness, AFO use, nonslip flooring, installation of stair safety handrails, and balance training are implemented. Psychological support: regular psychological assessment and participation in support groups are recommended to reduce social isolation and depression due to facial weakness.

References

  1. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science. 2010;329(5999):1650-1653. PMID: 20724583
  2. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet. 1992;2(1):26-30. PMID: 1363881
  3. van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet. 2003;35(4):315-317. PMID: 14634647
  4. Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy. Continuum (Minneap Minn). 2016;22(6):1916-1931. PMID: 27922494
  5. Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle. 2014;4:12. PMID: 24940479
  6. Ricci G, Ruggiero L, Vercelli L, et al. A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes. J Neurol. 2016;263(6):1204-1214. PMID: 27048327
  7. Giardina E, Cascella R, Colantoni L, et al. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines. Clin Genet. 2024. doi:10.1111/cge.14533
  8. Sacconi S, Lemmers RJLF, Balog J, et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet. 2013;93(4):744-751. PMID: 24075187
  9. Chen TH. New and developing therapies in facioscapulohumeral muscular dystrophy: a 2022 update. J Clin Med. 2022;11(23):7125. PMID: 36498699
  10. Deak KL, Lemmers RJ, Stajich JM, et al. Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4. Neurology. 2007;68(8):578-582. PMID: 17310024